Talk:Bioblast 2022

NextGen-O2k

MitoEAGLE

K-Regio MitoFit

O2k-Innovation

Houska-Award 2012

K-Regio MitoCom

Bioblast 2012

2022

 Bioblast 2022

Gnaiger E, Cardoso LHD, Tindle-Solomon L, Cocco P, eds (2022) Bioblast 2022: BEC inaugural conference. https://doi.org/10.26124/bec:2022-0001 - «Notes in Bioblast»

» Bioblast_2022 - Program overview

» Bioblast_2022 - Participants

» Bioblast_2022_-_Organisation

Bioblast 2022: Announcements

Co-write a BEC editorial: » BEC is the future.

Discussion: The future of BEC

back ▲

Join the discussion and contribute to a coauthored BEC editorial: BEC is the future.

• The lockdown phase was a bad timing for starting BEC, since it separated us by preventing real life meetings from happening . Bioblast 2022 is a re-start: We discuss the future of BEC .
• In advance, write to us and define the text to be posted in this discussion page under your name. Consider this as the initiation of a jointly published BEC editorial.

BEC strategies - some considerations

1. Beyond Gold Open Access - how can it be sustained?
   1. Definition: https://en.wikipedia.org/wiki/Open_access#Gold_OA
   2. BEC aims at 'Diamond Open Access' without article processing charge — free for authors and readers (see below: Oliveira Marcus F 2022-06-23).
   3. This is presently financed by Oroboros Instruments as a service to science.
   4. This model may be sustained by defining an upper limit of manuscripts processed per year, in line with a strategy beyond counting papers . With increasing numbers of submissions, the editors have to take decisions on accepting manuscripts for peer-review. Pre-publication peer review of MitoFit Preprints may play an increasing role in selecting preprints for BEC peer-review.
2. Editors of topical series
   1. The number of manuscripts per year may be extended, if volunteering editors take responsibility of guiding the publication of topical series.
   2. Series may be linked to a specific event with a defined timeline.
   3. Series may be linked to a specific topic with an open timeline.

A discussion on publishing

Gnaiger Erich 2022-06-16

• Academic institutions propagate the publication business by imprisoning academic careers into the impact factor lock-up. Do we need a change? How can we change? — Never alone, only by raising awareness collectively. Join DORA.

• ‘Open Access’ at a publication charge of $ 4620? Does the publication charge make a good journal? The paywall business model would collapse, when scientists refuse to do the journalism jobs in the financial interest of paywall journals.

» Elsevier and Pergamon Press

Chakrabarti Lisa 2022-06-23

Some first thoughts

I do like the idea of defining a better model for publishing. There is much to consider. Apart from cost of publication which for some journals is clearly excessive, there is a need to consider the workload of the research community. Agreeing to review a manuscript through to the publication point can be a lengthy and time-consuming process. more and more it is becoming difficult to find a wide community of invested reviewers.

Also, I do think people place more value on things that they have paid for (whether this is the right way to view things is a subject for elsewhere). Perhaps a reasonable fee is levied for each publication. This can be waived/traded, if the authors agree to review say 2-3 manuscripts within a certain amount of time. The reviewers can therefore feel they have been compensated for the time they spend. Researchers with more restricted funds still get to publish their high quality manuscripts.

Oliveira Marcus F 2022-06-23

In my view, we have experienced a revolution in the last 20 years in the scientific publication landscape as a consequence of the implementation of open access (OA) policies. In this new paradigm, readers now have broad and unrestricted access to scientific articles at no cost. However, the fastest-growing model of OA publishing (the golden route) transfers the costs from readers to scientists who produce the knowledge. The fees charged for publication in golden OA journals, the author publishing charges (APC), are in general expensive and have increased well above the inflation in the US and Europe in the last ten years.

There are several points to discuss on the future of BEC but I think the main one is which model of publishing should we adopt to be scientifically rigorous, but, at the same time, sustainable, fair, and inclusive for the bioenergeticists community? In this regard, we should be sensitive to the huge community of bioenergeticists around the world that are under enormous pressure to maintain their laboratories active and in many countries with very limited resources and financial support. Take the reality of African scientists where an average APC value is equivalent to half-year of a scholar's salary or that in many Latin American countries where despite having no robust scientific funding scientists are not allowed to request waivers and discounts because their countries are considered too rich to be eligible (https://www.nature.com/articles/d41586-021-02173-7; https://www.nature.com/articles/d41586-022-00864-3). Thus, in most of the southern hemisphere countries, the funding mechanisms are not robust enough in a way that scientists are not affluent enough to fund their research and support the covering of very expensive APC. Considering the rapid and profound changes in the scientific publishing landscape implemented by the Plan S initiative (started effectively in January 2021) this will basically separate the scientists that produce new knowledge (the North) from those that consume it (the South) (https://direct.mit.edu/qss/article/2/4/1123/107612/Assessing-the-effect-of-article-processing-charges).

As long as BEC is financially sustained by Oroboros, the Diamond OA route is possible desirable, but I strongly suspect that this would not be sustainable in the long term. In this sense, I think sooner or later, BEC will be forced to shift from the Diamond to Golden OA route. I don't see a problem in itself on the golden OA route, but I´m a vocal critic against the commercial exploitation that the giant publishers (Springer, Elsevier, and so on) that are being pushed by them through the Plan S initiative. Therefore, I think that BEC should take the lead as an OA journal to be sensitive to the heterogeneity of funding systems and implement clear actions to allow the publication of papers originating from countries established by the World Bank as low, middle, and upper-middle-income economies. Objectively, this would mean that BEC should establish clear policies to cap APC at reasonable values (let´s say ~ USD 500 per paper) and define clear policies for pricing discounts and waivers, especially considering the complexity of the funding mechanisms around the world. This would place BEC in a vanguard position fueling a virtual cycle that will maintain its financial health but at the same time will allow the inclusion of scientific knowledge from all over the world.

I truly hope that BEC should continue as a Diamond OA journal, but if it reaches a point that compromises its own financial existence, then a shift towards the Golden OA route is the way. However, in such a case, the sensitive issues pointed out above should be included, as a genuine act of the Gentle Science spirit, representing a milestone for a fairer, more affordable, and inclusive environment of scientific publishing free from market forces.

Cardoso Luiza HD 2022-06-23

Regarding DOAJ, there are some requirements for application (https://doaj.org/apply/guide/) related to the number of publications:

• Before applying to DOAJ, a new journal must demonstrate a publishing history of more than one year, or have published at least 10 articles.
• This is in addition to the standard requirement to publish a minimum of 5 research articles per year.

This requirement should will be met by BEC this year. However, here is another one that we should keep in mind:

• The proportion of published papers where at least one of the authors is an editor, editorial board member or reviewer must not exceed 20 % based on the research content of the latest two issues.

We have collected some information on journal indexing in the MitoPedia BEC:

» Journal indexing

Stiban Johnny 2022-06-24

As an associate editor and author in BEC, I feel very grateful for this opportunity. I am hopeful that this journal becomes indexed in Pubmed as well as in Scopus Scimago and other servers. This is absolutely required for universities to be able to use published papers in BEC for proMotion and tenure purposes. Also being indexed serves to increase publicity and visibility of the journal.

I have the following question that need to be discussed:

• What are the steps taken to index the journal?
• How can we apply for indexing in Scimago so that to get a Q number?
• Can we fundraise to have other companies than Oroboros contribute to BEC?
• What are the steps required to publicize BEC at our own institutions?
• How can we ensure associate editors and reviewers do their voluntary jobs in time (I have had trouble in my submissions and assigned manuscripts!)
• Can we offer reviewers some incentives to help them accept reviews? Maybe connect their reviews to Publons?
• Can we set up a biennial conference to highlight publications in BEC?
• Even though the journal is online, how about we make an online cover page with highlighted research.

back ▲

References

MitoPedia BEC - selected keywords

» MitoPedia: BEC

• Living Communications
• Journal indexing
• Paywall journalism
• Publication efficiency
• References in BEC https-format

Bioblast 2022 - MitoFit Preprints and BEC publications

	Reference	Year	View
Torres-Quesada 2022 MitoFit Kinase	Torres-Quesada O, Strich S, Stefan E (2022) Kinase perturbations redirect mitochondrial function. https://doi.org/10.26124/mitofit:2022-0011 — 2022-11-15 published in Bioenerg Commun 2022.13.	2022	MitoFit Preprints 2022.11. Kinase perturbations redirect mitochondrial function
Moreno-Sanchez 2022 MitoFit	Moreno-Sánchez R, Robledo-Cadena DX, Pacheco-Velázquez SC, Rodríguez-Enríquez S (2022) Estimation of energy pathway fluxes in cancer cells- beyond the Warburg effect. https://doi.org/10.26124/mitofit:2022-0024	2022	MitoFit Preprints 2022.24. Estimation of energy pathway fluxes in cancer cells- beyond the Warburg effect
Serna 2022 MitoFit	Serna JDC, Ramos VM, Cabral-Costa JV, Vilas-Boas EA, Amaral AG, Ohya G, da Silva CCC, Kowaltowski AJ (2022) Measuring mitochondrial Ca2+ efflux in isolated mitochondria and permeabilized cells. https://doi.org/10.26124/mitofit:2022-0021 — 2022-07-28 published in Bioenerg Commun 2022.7.	2022	MitoFit Preprints 2022.21. Measuring mitochondrial Ca2+ efflux in isolated mitochondria and permeabilized cells
Bombaca 2022 MitoFit	Bombaça ACS, Menna-Barreto RFS (2022) Mitochondrial plasticity in trypanosomatids as a stress adaptation mechanism. https://doi.org/10.26124/mitofit:2022-0016 — 2022-12-23 published in Bioenerg Commun 2022.20.	2022	MitoFit Preprints 2022.16. Mitochondrial plasticity in trypanosomatids as a stress adaptation mechanism
Alencar 2022 MitoFit	Alencar MB, Ramos EV, Silber AM, Zíková A, Oliveira MF (2022) The extraordinary energy metabolism of the bloodstream Trypanosoma brucei forms: a critical review and a hypothesis. https://doi.org/10.26124/mitofit:2022-0009.v2 — 2022-12-05 published in Bioenerg Commun 2022.17.	2022	MitoFit Preprints 2022.09.v2. A unifying hypothesis for the extraordinary energy metabolism of bloodstream Trypanosoma brucei
Chicco 2022 MitoFit	Chicco AJ, Zilhaver PT, Whitcomb LA, Fresa KJ, Izon CS, Gonzalez-Franquesa A, Izon CS, Dometita C, Irving BA, Garcia-Roves PM (2022) Resolving the Rotenone Paradox: elucidating the complexity of multi-substrate respirometry protocols. https://doi.org/10.26124/mitofit:2022-0017	2022	MitoFit Preprints 2022.17. Resolving the Rotenone Paradox: elucidating the complexity of multi-substrate respirometry protocols
Heichler 2022 MitoFit	Heichler C, Nagy M, Wolf P (2022) Evaluation of hepatotoxic effects of acetaminophen on HepG2 cells by parallel real-time monitoring in a multi-sensor analysis platform for automated cell-based assays. https://doi.org/10.26124/mitofit:2022-0006 — 2022-07-06 published in Bioenerg Commun 2022.6.	2022	MitoFit Preprints 2022.06. Evaluation of hepatotoxic effects of acetaminophen on HepG2 cells by parallel real-time monitoring in a multi-sensor analysis platform for automated cell-based assays
Karavyraki 2022 MitoFit	Karavyraki M, Gnaiger E, Porter RK (2022) A comparison of bioenergetics in human tongue pre-cancerous dysplastic oral keratinocytes and squamous cancer cells. https://doi.org/10.26124/mitofit:2022-0022 — 2022-11-11 published in Bioenerg Commun 2022.11.	2022	MitoFit Preprints 2022.22. A comparison of bioenergetics in human tongue pre-cancerous dysplastic oral keratinocytes and squamous cancer cells
Baglivo 2022 MitoFit-QC	Baglivo E, Cardoso LHD, Cecatto C, Gnaiger E (2022) Statistical analysis of instrumental reproducibility as internal quality control in high-resolution respirometry. https://doi.org/10.26124/mitofit:2022-0018.v2 — 2022-08-04 published in Bioenerg Commun 2022.8.	2022	MitoFit Preprints 2022.18. Statistical analysis of instrumental reproducibility as internal quality control in high-resolution respirometry
Abed Rabbo 2022 MitoFit	Abed Rabbo M, Stiban J (2022) NUBPL: a mitochondrial Complex I deficiency disorder. https://doi.org/10.26124/mitofit:2022-0005 — 2022-06-28 published in Bioenerg Commun 2022.3.	2022	MitoFit Preprints 2022.05. NUBPL: a mitochondrial Complex I deficiency disorder
Komlodi 2022 MitoFit	Komlódi T, Tretter L (2022) The protonmotive force – not merely membrane potential. https://doi.org/10.26124/mitofit:2022-0012 — 2022-11-29 published in Bioenerg Commun 2022.16.	2022	MitoFit Preprints 2022.12. The protonmotive force - not merely membrane potential
Roach 2022 MitoFit	Roach T (2022) Chlorophyll fluorescence of Chlamydomonas reinhardtii; insights into the complexities. https://doi.org/10.26124/mitofit:2022-0023.v2 — 2022-11-10 published in Bioenerg Commun 2022.10.	2022	MitoFit Preprints 2022.23.v2. Chlorophyll fluorescence of Chlamydomonas reinhardtii; insights into the complexities
Vera Vives 2022 MitoFit	Vera-Vives AM, Perin G, Morosinotto T (2022) The robustness of NextGen-O2k for building PI curves in microalgae. https://doi.org/10.26124/mitofit:2022-0019 — 2022-12-15 published in Bioenerg Commun 2022.19.	2022	MitoFit Preprints 2022.19. The robustness of NextGen-O2k for building PI curves in microalgae
Posch 2022 MitoFit	Posch W, Dichtl S, Zaderer V, Lass-Flörl C, Wilflingseder D (2022) How to optimize respiratory models for SARS-CoV-2 research. https://doi.org/10.26124/mitofit:2022-0004 — 2022-09-08 published in Bioenerg Commun 2022.9.	2022	MitoFit Preprints 2022.04. How to optimize respiratory models for SARS-CoV-2 research
Heimler 2022 MitoFit	Heimler SR, Phang HJ, Bergstrom J, Mahapatra G, Dozier S, Gnaiger E, Molina AJA (2022) Platelet bioenergetics are associated with resting metabolic rate and exercise capacity in older women. https://doi.org/10.26124/mitofit:2022-0007 — 2022-06-28 published in Bioenerg Commun 2022.2.	2022	MitoFit Preprints 2022.07. Platelet bioenergetics associated with resting metabolic rate and exercise capacity in older women
Gnaiger 2022.1 Bioenerg Commun	Gnaiger E, Cardoso LHD, Tindle-Solomon L, Cocco P, eds (2022) Bioblast 2022: BEC inaugural conference. https://doi.org/10.26124/bec:2022-0001	2022	Bioenerg Commun 2022.01. published online 2022-06-18
Dambrova 2022 MitoFit	Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. https://doi.org/10.26124/mitofit:2022-0020 2022-11-25 published in Bioenerg Commun 2022.15.	2022	MitoFit Preprints 2022.20. Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets
Aasander Frostner 2022 MitoFit	Åsander Frostner E, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. https://doi.org/10.26124/mitofit:2022-0014 — 2022-06-28 published in Bioenerg Commun 2022.4.	2022	MitoFit Preprints 2022.14. Towards a treatment for mitochondrial disease: current compounds in clinical development
Went 2021 MitoFit PB	Went N, Di Marcello M, Gnaiger E (2021) Oxygen dependence of photosynthesis and light-enhanced dark respiration studied by High-Resolution PhotoRespirometry. https://doi.org/10.26124/mitofit:2021-0005	2021	MitoFit Preprints 2021.05. Oxygen dependence of photosynthesis and light-enhanced dark respiration studied by High-Resolution PhotoRespirometry

back ▲